IA
SRNE

IFG Advisory’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

IFG Advisory’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,000
Closed -$17K – 531
2022
Q4 		$17K Sell
20,000
-39
-0.2% -$52 ﹤0.01% 488
2022
Q3 		$31K Buy
20,039
+39
+0.2% +$88 ﹤0.01% 509
2022
Q2 		$40K Hold
20,000
– – ﹤0.01% 456
2022
Q1 		$46K Buy
20,000
+4,100
+26% +$12.8K ﹤0.01% 485
2021
Q4 		$73K Sell
15,900
-2,000
-11% -$12.4K 0.01% 493
2021
Q3 		$136K Buy
+17,900
New +$152K 0.01% 473

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

IFG Advisory's SRNE Position: Q1 2023 in Review

IFG Advisory sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 20,000 shares — an estimated $17K sold.

IFG Advisory first reported a position in SRNE in Q3 2021 and held it in 6 quarters. The position peaked at $136K in Q3 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • IFG Advisory reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • IFG Advisory sold 20,000 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $17K.
  • IFG Advisory first reported a position in Sorrento Therapeutics, Inc. in Q3 2021 and held it in 6 quarters.
  • IFG Advisory's Sorrento Therapeutics, Inc. position peaked at $136K in Q3 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on IFG Advisory's 13F filing for Q1 2023, filed 26 Apr 2023.